Olympic Therapeutics AG

A new class of drugs against MRSA

Overview

Olympic Therapeutics AG -
A new approach to treating MRSA

At a glance

Bandage Icon

Antibiotics

Louis Pasteur coined the phrase "life prevents life" after discovering in 1877 that some strains of bacteria inhibit the growth of germs.

Syringe Icon

Penicillin

Alexander Fleming began in 1928 with a forgotten and moldy staphylococcus culture dish at St. Mary’s Hospital in London.

Microscope Icon

Resistance

Due to the irresponsible use of antibiotics, resistance to new antibiotics has developed worldwide.

cell Icon

Bacteriophages

To help this ever-growing group of patients, we rely on the use of highly effective bacteriophages.

Business Model

Development of a new technology for the treatment of MRSA using bacteriophages

Key Person

Management

Hans Balz Portrait

Hans Balz

Director and Chairman of the Board of Directors, Olympic Therapeutics AG

MBA – Clinic Consultant

  • Certified Clinical Pharmaceutical Representative clinical trials - in vitro/in vivo

  • Field Sales Manager, Pharmaceuticals

  • Extensive expertise in Microbiology and Infectiology

  • Certified Stockbroker

  • International Experience

Competencies

  • Project and Investment Management

  • Biopharmaceutical R&D

  • Financial Sector / Banking

  • Business Planning and Strategy

  • Bacteriophage R&D USA, Seattle/Georgia, Tbilisi, Europe

Nicolai Colshorn

  • Board Member of several Swiss companies

  • Director, ECON Commercial Company GmbH

  • Authorized Signatory, Olympic Therapeutics AG

  • Finance and Accounting

Competencies

  • Legal and Contract Management

  • Investment Management

  • Compliance

  • Corporate Law

Strategy

Combating Bacterial Infections Without the Use of Antibiotics

Research

Our research draws on decades of experience

Identification

From existing bacteriophages, we identify the best candidates

Finance

Capital increase and onboarding of selected investors

Development

Development of the final bacteriophages for the treatment of MRSA and other bacterial infections

Rollout

Start of marketing after completion of the development phase

Exit

Sale or licensing of the final bacteriophages

Market

Overview

The global pharmaceutical industry

Positioning

Sweet spot between biopharmaceuticals and major players

Trends

These trends determine industry development

1

Patients

  • Global antibiotic crisis

  • Fewer and fewer patients trust the use of antibiotics

  • More and more hospitals are facing problems with MRSA

  • Significant global growth

2

Personalization

  • Individually adaptable active substances are the trend of the future

  • Bacteriophages can be rapidly and individually tailored to the specific bacterium

3

Resistance

  • No resistance possible, as bacteriophages specialize in bacteria as host cells

  • No side effects as with antibiotics

Business model

Overview

Four pillars for an excellent future outlook

Strong future potential driven by:

  • Experienced management

  • Holistic approach

  • Focus on innovative technology

Status

Implementation and planning

Implemented

  • Company founding

  • Research & Development to date

  • Initial funding

  • Conclusion of agreements with partner companies

  • Product identification

Shareholder structure

  • Current share capital: CHF 100,000.00

  • Investments during the development phase by the CEO and main shareholder, as well as strategic investors

  • Second capitalization round planned with a volume of TEUR 2,000.00

  • The third financing round is planned to have a volume of TEUR 25,000.00

Goals

  • Development of bacteriophages

  • Patenting

  • Clinical Phase I

  • Clinical Phase II

  • Exit through sale or licensing

Capital market

Investment Highlights

Innovative technology with high upside

  • Innovative business model Diversification through a holistic approach, with an exceptionally broad and globally customizable range of applications

  • Future-proof positioning With its development approach, Olympic Therapeutics AG strongly addresses the continuously growing long-term challenge of antibiotic resistance.

  • Recurring revenues after rollout Through the ability to license the developed bacteriophages, long-term recurring revenues can be generated

  • Additional revenue potential through further project development Based on the first finalized product candidate, additional bacterial infections can be identified and corresponding bacteriophages can be newly applied

positive Investment

Capital market strategy

Gain visibility

Wall street Bulle auf weißem Hintergrund

  • Engagement with capital market partners

  • Initial capital measure in the form of a private placement to selected investors

  • Second capital measure to follow through a public offering or a strategic investor

  • Creation of liquidity for the securities through listing on a trading platform or offering to shareholders

  • Positioning as a growth stock, with no dividend strategy planned

Financial calendar

Current and upcoming dates for 2026

Annual General Meeting – see official gazette of the Canton of Zug, Q1/Q2 2026

 

30 June 2026 – General Meeting of Shareholders

Development and acquisition of proprietary phages
(Intellectual property / global patent rights)

Pre-clinical manufacturing

Europe / Georgia / Tbilisi – Eliava Bacteriophage Institute
USA / Seattle – Laboratories Inc.